Brief introduction of 3-Phenyl-6-chloropyridazine

Do you like my blog? If you like, you can also browse other articles about this kind. Thanks for taking the time to read the blog about 20375-65-9

20375-65-9, Name is 3-Phenyl-6-chloropyridazine, belongs to pyridazine compound, is a common compound. Safety of 3-Phenyl-6-chloropyridazineIn an article, once mentioned the new application about 20375-65-9.

The tetrapeptide H-Arg-Gly-Asp-Ser-OH (1) (RGDS), representing a recognition sequence of fibrinogen for its platelet receptor GP IIb-IIIa (integrin alpha(IIb)beta3), served as lead compound for the development of highly potent and selective fibrinogen receptor antagonists. Replacement of the N- terminal arginine by p-amidinophenylalanine or the Gly moiety by m- aminobenzoic acid led to compounds which are superior to the lead peptide with regard to activity and selectivity for GP IIb-IIIa vs the closely related vitronectin receptor alpha(v)beta3. By random screening [(p- amidinobenzenesulfonamido)ethyl]-p-phenoxyacetic acid derivatives have been identified as fibrinogen receptor antagonists. Further structure-activity relationship studies culminated in the preparation of N-[N-[N-(p- amidinobenzoyl)-beta-alanyl]-L-alpha-aspartyl]-3-phenyl-L-alanine (29h, Ro 43- 5054) and [[1-[N-(p-amidinobenzoyl)-L-tyrosyl]-4-piperidinyl]oxy]acetic acid (37f, Ro 44-9883), which exhibit very high activity as platelet aggregation inhibitors (IC50s 0.06 and 0.03 muM, respectively, human PRP/ADP) as well as marked selectivity for GP IIb-IIIa vs alpha(v)beta3. Since the activity of 37f in dogs declines according to a two-compartment model with an initial phase having a t( 1/2 ) of 8 min and a second phase with a t( 1/2 ) of 110 min, this compound is a suitable candidate for the development as iv platelet inhibitor.

Do you like my blog? If you like, you can also browse other articles about this kind. Thanks for taking the time to read the blog about 20375-65-9

Reference:
Pyridazine – Wikipedia,
Pyridazine | C4H4N2589 – PubChem